



Role of Traditional Medicinal Plants in Modern Drug Development: Phytochemical Insights, Mechanistic Pathways, and Translational Applications in Therapeutics

Dr. Jonathan Michael Whitmore^{1*}, Amanda Claire Harrington², Dr. Samuel David Reynolds³

¹ PhD, Department of Pharmaceutical Sciences, Center for Nanomedicine and Drug Delivery, University of California San Diego, USA.

² PharmD, PhD, Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.

³ PhD, Department of Biomedical Engineering and Oncology Nanotherapeutics, Johns Hopkins University School of Medicine, USA.

* Corresponding Author: **Dr. Jonathan Michael Whitmore**

Article Info

ISSN (online): 3107-393X

Volume: 01

Issue: 01

January – February 2024

Received: 17-11-2023

Accepted: 19-12-2023

Published: 21-01-2024

Page No: 57-62

Abstract

Traditional medicinal plants represent a rich repository of bioactive compounds that have significantly influenced modern pharmaceutical development. This review examines the phytochemical profiles, molecular mechanisms, and therapeutic applications of plant-derived natural products in contemporary drug discovery. Key phytochemical classes including alkaloids, flavonoids, terpenoids, saponins, and phenolic compounds are analyzed for their mechanistic pathways involving antioxidant activity, enzyme inhibition, receptor modulation, and signal transduction interference. The translational pipeline from ethnopharmacological knowledge to clinical therapeutics is critically evaluated, highlighting successful drug development examples in oncology, cardiology, neurology, and infectious diseases. Despite substantial progress, challenges persist regarding standardization, bioavailability optimization, and clinical translation. This comprehensive analysis underscores the continued relevance of medicinal plants as valuable sources for novel therapeutic agents and provides insights into future directions for phytochemical-based drug development.

DOI:

Keywords: Medicinal Plants, Phytochemicals, Drug Discovery, Molecular Mechanisms, Natural Products, Therapeutic Applications

1. Introduction

The discovery and development of pharmacologically active compounds from natural sources have historically served as cornerstones of modern therapeutics. Traditional medicinal plants, utilized across diverse cultures for millennia, have yielded numerous clinically significant drugs including morphine, quinine, digoxin, and paclitaxel^[1, 2]. These success stories exemplify the pharmaceutical potential embedded within plant secondary metabolites, which have evolved as sophisticated chemical defense mechanisms and signaling molecules^[3]. Contemporary drug discovery faces increasing challenges including rising development costs, declining approval rates, and the urgent need for novel therapeutic scaffolds to address emerging diseases and drug resistance^[4]. In this context, medicinal plants offer chemically diverse molecular libraries that complement synthetic and combinatorial chemistry approaches^[5].

Phytochemicals represent structurally complex natural products optimized through evolutionary processes, exhibiting remarkable chemical diversity and biological specificity^[6]. Unlike synthetic compounds designed through rational drug design, plant metabolites often display multi-target pharmacology and favorable absorption, distribution, metabolism, and excretion

(ADME) profiles due to their biological origin [7]. Recent advances in analytical technologies, including high-resolution mass spectrometry, nuclear magnetic resonance spectroscopy, and computational chemistry, have dramatically enhanced our capacity to identify, characterize, and optimize bioactive phytochemicals [8, 9]. Furthermore, systems pharmacology and network biology approaches now enable comprehensive understanding of multi-component, multi-target mechanisms underlying traditional medicine efficacy [10].

This review provides a comprehensive analysis of traditional medicinal plants in modern drug development, focusing on phytochemical composition, molecular mechanisms of action, and translational applications. We examine major classes of bioactive compounds, elucidate their pharmacological pathways at molecular and cellular levels, and evaluate their contributions to contemporary therapeutics. Additionally, we address critical challenges in standardization, bioavailability optimization, and clinical translation that must be overcome to fully realize the pharmaceutical potential of medicinal plants.

2. Phytochemical Profiles of Medicinal Plants

2.1. Alkaloids and Flavonoids

Alkaloids constitute nitrogen-containing heterocyclic compounds characterized by pronounced pharmacological activity and structural complexity. These secondary metabolites, biosynthesized from amino acid precursors, demonstrate diverse therapeutic applications ranging from analgesic to anti-cancer effects [11]. Morphine and codeine from *Papaver somniferum* exemplify opioid alkaloids acting on μ -opioid receptors for pain management, while vincristine and vinblastine from *Catharanthus roseus* serve as established chemotherapeutic agents targeting microtubule dynamics [12]. Berberine, an isoquinoline alkaloid found in *Berberis* species, exhibits multi-target pharmacology including AMP-activated protein kinase (AMPK) activation, glucose metabolism regulation, and antimicrobial activity [13].

Flavonoids represent polyphenolic compounds with a characteristic C6-C3-C6 carbon skeleton, widely distributed across plant species and subdivided into flavones, flavonols, flavanones, isoflavones, and anthocyanins [14]. These compounds demonstrate potent antioxidant properties through radical scavenging and metal chelation, alongside anti-inflammatory effects mediated by nuclear factor kappa B (NF- κ B) and cyclooxygenase (COX) pathway inhibition [15]. Quercetin, a ubiquitous flavonol, modulates multiple signaling cascades including mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt pathways, contributing to cardiovascular and neuroprotective effects [16]. Epigallocatechin gallate (EGCG) from *Camellia sinensis* exhibits chemopreventive properties through histone deacetylase inhibition and protein kinase C modulation [17].

2.2. Terpenoids and Saponins

Terpenoids comprise the largest class of natural products, characterized by isoprene unit polymerization and classified according to carbon number into monoterpenoids (C10), sesquiterpenoids (C15), diterpenoids (C20), and triterpenoids (C30) [18]. Artemisinin, a sesquiterpenoid lactone from *Artemisia annua*, represents a breakthrough antimalarial agent acting through endoperoxide bridge-mediated free radical generation and heme alkylation in *Plasmodium*

parasites [19]. Paclitaxel, a diterpenoid alkaloid from *Taxus brevifolia*, stabilizes microtubules against depolymerization, disrupting mitotic spindle function and inducing apoptosis in cancer cells [20]. Triptolide from *Tripterygium wilfordii* demonstrates immunosuppressive and anti-inflammatory activities through NF- κ B inhibition and T-cell proliferation suppression [21].

Saponins are amphipathic glycosides consisting of triterpenoid or steroid aglycones attached to sugar moieties, conferring surfactant properties and membrane interactions [22]. Ginsenosides from *Panax ginseng* species exhibit adaptogenic effects through hypothalamic-pituitary-adrenal axis modulation and glucocorticoid receptor regulation [23]. These compounds demonstrate neuroprotective mechanisms including antioxidant enzyme upregulation, neurotrophic factor enhancement, and mitochondrial dysfunction prevention [24]. Glycyrrhizin from *Glycyrrhiza glabra* displays anti-inflammatory activity through 11β -hydroxysteroid dehydrogenase inhibition and cortisol metabolism alteration, alongside antiviral effects against various pathogens [25].

2.3. Phenolic Acids and Glycosides

Phenolic acids, including hydroxybenzoic and hydroxycinnamic acid derivatives, represent simple phenolic compounds with significant biological activities. Caffeic acid, ferulic acid, and chlorogenic acid demonstrate potent antioxidant properties through hydrogen atom transfer and electron donation mechanisms [26]. These compounds inhibit lipid peroxidation, scavenge reactive oxygen species (ROS), and upregulate phase II detoxification enzymes through nuclear factor erythroid 2-related factor 2 (Nrf2) pathway activation [27]. Curcumin from *Curcuma longa*, though technically a diarylheptanoid, exhibits pleiotropic pharmacological effects including anti-inflammatory, antioxidant, and anti-cancer activities mediated by multiple molecular targets [28].

Cardiac glycosides, characterized by steroid nuclei attached to sugar residues, represent classical examples of medicinal plant-derived cardiovascular drugs. Digoxin and digitoxin from *Digitalis* species inhibit Na⁺/K⁺-ATPase, increasing intracellular calcium concentrations and enhancing cardiac contractility [29]. Beyond their traditional cardiotonic applications, recent investigations have revealed anti-cancer potential through autophagy induction, immune checkpoint modulation, and cancer stem cell targeting [30]. These findings exemplify the continued discovery of novel pharmacological activities in well-established phytochemicals.

3. Mechanistic Insights and Molecular Targets

3.1. Antioxidant and Anti-inflammatory Pathways

Oxidative stress and chronic inflammation represent interconnected pathological processes underlying numerous diseases including cancer, cardiovascular disorders, and neurodegenerative conditions [31]. Phytochemicals combat oxidative damage through direct ROS scavenging and indirect mechanisms involving antioxidant enzyme induction. The Nrf2-Kelch-like ECH-associated protein 1 (Keap1) pathway serves as a master regulator of cellular antioxidant responses, with numerous phytochemicals promoting Nrf2 nuclear translocation and antioxidant response element (ARE)-mediated gene transcription [32]. Polyphenols, including resveratrol and curcumin, activate Nrf2 through Keap1 cysteine residue modification,

upregulating heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase-1 (NQO1), and glutathione-S-transferase (GST) [33].

Anti-inflammatory mechanisms of phytochemicals involve multiple signaling pathway modulations. NF- κ B, a central pro-inflammatory transcription factor, is inhibited by various plant compounds through I-kappa B kinase (IKK) suppression, preventing nuclear translocation and inflammatory cytokine expression [34]. Flavonoids and terpenoids demonstrate COX-2 and inducible nitric oxide synthase (iNOS) downregulation, reducing prostaglandin E2 and nitric oxide production [35]. Additionally, MAPK pathway interference, particularly extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK inhibition, contributes to anti-inflammatory effects by suppressing activator protein-1 (AP-1) activation [36].

3.2. Enzyme Inhibition and Receptor Modulation

Phytochemicals demonstrate remarkable specificity in enzyme inhibition, providing valuable pharmacological tools and therapeutic leads. Alkaloids such as berberine and palmatine inhibit acetylcholinesterase, offering potential for Alzheimer's disease management through enhanced cholinergic neurotransmission [37]. Polyphenolic compounds inhibit key metabolic enzymes including α -glucosidase and α -amylase, delaying carbohydrate digestion and glucose absorption for diabetes management [38]. Epigallocatechin gallate competitively inhibits dihydrofolate reductase and DNA methyltransferases, contributing to anti-cancer effects through folate metabolism disruption and epigenetic modifications [39].

Receptor modulation represents another critical mechanism whereby phytochemicals exert pharmacological effects. Isoflavones such as genistein act as selective estrogen receptor modulators (SERMs), exhibiting tissue-selective estrogenic or anti-estrogenic effects valuable for hormone-dependent cancer and osteoporosis [40]. Cannabinoids from *Cannabis sativa* interact with endocannabinoid receptors CB1 and CB2, modulating pain perception, appetite, and immune responses [41]. Ginsenosides demonstrate glucocorticoid receptor and peroxisome proliferator-activated receptor (PPAR) modulation, influencing metabolic homeostasis and inflammatory responses [42].

3.3. Cytoprotective and Chemoprotective Mechanisms

Cytoprotection mediated by phytochemicals involves multiple cellular defense mechanisms including apoptosis inhibition, autophagy regulation, and mitochondrial function preservation. Flavonoids protect against oxidative injury through mitochondrial permeability transition pore stabilization and cytochrome c release prevention, thereby blocking intrinsic apoptotic pathways [43]. Silymarin from *Silybum marianum* demonstrates hepatoprotective effects through antioxidant activity, membrane stabilization, and hepatocyte regeneration stimulation, validated in various liver injury models [44].

Chemopreventive mechanisms involve interference with carcinogenesis stages including initiation, promotion, and progression. Phase II enzyme induction through Nrf2 activation enhances xenobiotic metabolism and carcinogen detoxification [45]. Sulforaphane from *Brassica* vegetables induces quinone reductase and glutathione S-transferase, facilitating carcinogen elimination [46]. Additionally,

phytochemicals modulate cell cycle regulatory proteins including cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors, inducing cell cycle arrest at various checkpoints [47]. Apoptosis induction through both extrinsic (death receptor) and intrinsic (mitochondrial) pathways represents a crucial chemopreventive mechanism, with compounds like resveratrol and curcumin activating caspase cascades [48].

4. Applications in Modern Drug Development

4.1. Anti-cancer Drug Discovery

Traditional medicinal plants have yielded numerous clinically successful anti-cancer agents representing diverse chemical scaffolds and mechanisms of action. Vinca alkaloids (vincristine, vinblastine) and taxanes (paclitaxel, docetaxel) exemplify plant-derived chemotherapeutics targeting microtubule dynamics, with widespread clinical application across various malignancies [49]. Camptothecin derivatives including irinotecan and topotecan, originally isolated from *Camptotheca acuminata*, inhibit topoisomerase I, preventing DNA relegation and inducing cancer cell death [50]. Podophyllotoxin from *Podophyllum* species served as the structural template for etoposide and teniposide, topoisomerase II inhibitors used in leukemia, lymphoma, and solid tumor treatment [51].

Contemporary anti-cancer drug discovery continues to leverage medicinal plant biodiversity. Combretastatin A-4 phosphate from *Combretum caffrum* demonstrates vascular disrupting agent properties, selectively targeting tumor vasculature and currently under clinical investigation [52]. Homoharringtonine from *Cephalotaxus harringtonia* gained FDA approval for chronic myeloid leukemia treatment through protein synthesis inhibition at the ribosomal level. Natural product-inspired semi-synthesis approaches have generated improved analogues with enhanced efficacy and reduced toxicity, exemplified by nab-paclitaxel's improved solubility and tumor delivery profile.

4.2. Cardiovascular, Metabolic, and Neuroprotective Agents

Cardiovascular therapeutics derived from medicinal plants include cardiac glycosides, antihypertensives, and antiarrhythmic agents. Beyond digoxin's established use, resveratrol from *Vitis vinifera* demonstrates cardioprotective effects through sirtuin activation, endothelial nitric oxide synthase enhancement, and atherosclerotic plaque stabilization. Berberine exhibits lipid-lowering properties comparable to statins through low-density lipoprotein receptor upregulation and proprotein convertase subtilisin/kexin type 9 (PCSK9) reduction, with clinical validation in dyslipidemia management.

Metabolic disorder management has benefited substantially from phytochemical-based interventions. Metformin, derived from galegine in *Galega officinalis*, represents the first-line type 2 diabetes medication acting through AMPK activation and hepatic gluconeogenesis suppression. Numerous medicinal plant extracts demonstrate anti-diabetic potential through multiple mechanisms including insulin secretion enhancement, insulin sensitivity improvement, and glucose uptake stimulation. Neuroprotective applications encompass Alzheimer's disease, Parkinson's disease, and stroke interventions, with compounds like huperzine A from *Huperzia serrata* providing acetylcholinesterase inhibition and cognitive enhancement.

4.3. Anti-infective Therapeutics

Antimalarial drug development exemplifies successful translation of traditional medicine to modern therapeutics. Artemisinin and its derivatives constitute the cornerstone of contemporary malaria treatment, particularly artemisinin-based combination therapies (ACTs) recommended by the World Health Organization. Quinine, historically extracted from *Cinchona* species, pioneered antimalarial pharmacotherapy and remains relevant for severe malaria cases. The continued emergence of drug-resistant *Plasmodium* strains necessitates ongoing investigation of novel plant-derived antimalarials, with compounds like cryptolepine from *Cryptolepis sanguinolenta* demonstrating promising activity.

Antibacterial and antiviral applications of phytochemicals address rising antimicrobial resistance and emerging infectious diseases. Berberine demonstrates broad-spectrum antibacterial activity through multiple mechanisms including cell membrane disruption, efflux pump inhibition, and biofilm formation interference. Antiviral phytochemicals target various stages of viral replication, with glycyrrhizin inhibiting viral attachment and penetration, while baicalin from *Scutellaria baicalensis* interferes with viral polymerase activity. The COVID-19 pandemic has intensified research into antiviral phytochemicals, with numerous compounds demonstrating *in vitro* activity against SARS-CoV-2 through protease inhibition and spike protein interaction interference.

5. Challenges and Translational Perspectives

5.1. Standardization and Quality Control

Phytochemical composition variability arising from genetic diversity, environmental conditions, harvest timing, and post-harvest processing presents significant standardization challenges. Establishing chemically defined extracts with consistent bioactive compound concentrations requires sophisticated analytical methodology and quality control protocols. High-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-MS) enable comprehensive phytochemical profiling and quantification. DNA barcoding and molecular authentication techniques prevent species substitution and adulteration, ensuring botanical identity verification.

Good manufacturing practice (GMP) compliance and regulatory standardization remain critical for commercial development of botanical therapeutics. The European Medicines Agency and FDA have established guidelines for botanical drug development, requiring comprehensive chemical characterization, manufacturing consistency, and clinical evidence. Metabolomics approaches utilizing nuclear magnetic resonance spectroscopy and mass spectrometry-based profiling provide holistic quality assessment beyond marker compound quantification.

5.2. Bioavailability and Formulation Optimization

Limited oral bioavailability of many phytochemicals, arising from poor aqueous solubility, extensive first-pass metabolism, and efflux transporter activity, impedes clinical translation. Curcumin exemplifies this challenge, exhibiting potent *in vitro* activity but minimal systemic exposure following oral administration due to rapid glucuronidation and sulfation. Nanotechnology-based delivery systems including liposomes, solid lipid nanoparticles, polymeric nanoparticles, and nanoemulsions enhance bioavailability through improved solubility, permeability, and metabolic stability. Piperine co-administration demonstrates bioenhancing effects through cytochrome P450 and P-glycoprotein inhibition, substantially increasing curcumin bioavailability.

Pharmaceutical co-crystal formation, self-emulsifying drug delivery systems, and cyclodextrin complexation represent additional strategies for bioavailability enhancement. Structure modification through semi-synthesis improves pharmacokinetic properties while maintaining pharmacological activity, as demonstrated by artemisinin derivatives with enhanced stability and antimalarial efficacy. Prodrug approaches convert poorly absorbed compounds into chemically modified derivatives that undergo *in vivo* activation, exemplified by phosphate ester prodrugs of poorly soluble flavonoids.

5.3. Preclinical to Clinical Translation

The translational gap between promising preclinical findings and clinical efficacy represents a critical bottleneck in phytochemical-based drug development. Discrepancies between *in vitro* concentrations demonstrating biological activity and achievable *in vivo* exposure often undermine clinical translation. Pharmacokinetic-pharmacodynamic modeling and physiologically-based pharmacokinetic simulations facilitate dose selection and exposure-response predictions for clinical trials. Multi-component botanical preparations present additional complexity requiring systems pharmacology approaches to elucidate synergistic interactions and collective therapeutic effects.

Clinical trial design for botanical drugs necessitates consideration of delayed onset effects, multi-target mechanisms, and individualized responses based on metabolic polymorphisms. Adaptive trial designs and biomarker-driven patient stratification may improve success rates for phytochemical therapeutics. Regulatory pathways specifically addressing botanical drug development, including the FDA's Botanical Drug Guidance, provide frameworks for demonstrating safety and efficacy while acknowledging the unique characteristics of plant-derived medicines.

Table 1: Selected Traditional Medicinal Plants, Key Phytochemicals, and Therapeutic Applications

Plant Species	Family	Key Phytochemicals	Therapeutic Applications
<i>Catharanthus roseus</i>	Apocynaceae	Vincristine, Vinblastine	Anti-cancer (leukemia, lymphoma)
<i>Papaver somniferum</i>	Papaveraceae	Morphine, Codeine	Analgesic, Antitussive
<i>Taxus brevifolia</i>	Taxaceae	Paclitaxel	Anti-cancer (breast, ovarian, lung)
<i>Artemisia annua</i>	Asteraceae	Artemisinin	Antimalarial
<i>Digitalis purpurea</i>	Plantaginaceae	Digoxin, Digitoxin	Cardiac glycosides, Heart failure
<i>Panax ginseng</i>	Araliaceae	Ginsenosides	Adaptogenic, Neuroprotective
<i>Curcuma longa</i>	Zingiberaceae	Curcumin	Anti-inflammatory, Antioxidant
<i>Camellia sinensis</i>	Theaceae	EGCG, Catechins	Chemopreventive, Antioxidant
<i>Berberis species</i>	Berberidaceae	Berberine	Antimicrobial, Antidiabetic
<i>Glycyrrhiza glabra</i>	Fabaceae	Glycyrrhizin	Anti-inflammatory, Antiviral

6. Conclusion

Traditional medicinal plants continue to serve as invaluable sources of bioactive compounds with demonstrated therapeutic potential across diverse disease areas. The phytochemical diversity encompassing alkaloids, flavonoids, terpenoids, saponins, and phenolic compounds provides structurally complex molecular scaffolds with multi-target pharmacological activities. Mechanistic investigations have elucidated molecular and cellular pathways underlying their therapeutic effects, including antioxidant and anti-inflammatory activities, enzyme inhibition, receptor modulation, and cytoprotective mechanisms. Successful translation of plant-derived compounds into clinically approved drugs, particularly in oncology, infectious diseases, and cardiovascular medicine, validates the pharmaceutical significance of this approach.

Despite remarkable achievements, significant challenges persist in standardization, bioavailability optimization, and clinical translation. Advanced analytical technologies, innovative formulation strategies, and systems pharmacology approaches offer promising solutions to overcome these limitations. Future directions should emphasize integration of ethnopharmacological knowledge with cutting-edge technologies including genomics, metabolomics, and artificial intelligence for accelerated drug discovery. Sustainable sourcing, conservation strategies, and biotechnological production methods must be prioritized to ensure continued access to medicinal plant resources. As modern medicine increasingly recognizes the value of natural product-based therapeutics, traditional medicinal plants will undoubtedly continue contributing to the pharmaceutical armamentarium, addressing unmet medical needs and improving global health outcomes.

7. References

- Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *J Nat Prod*. 2020;83(3):770–803.
- Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. *Nat Rev Drug Discov*. 2021;20(3):200–216.
- Wink M. Modes of action of herbal medicines and plant secondary metabolites. *Medicines (Basel)*. 2015;2(3):251–286.
- Paul SM, Mytelka DS, Dunwiddie CT, *et al*. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nat Rev Drug Discov*. 2010;9(3):203–214.
- Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. *Nat Rev Drug Discov*. 2015;14(2):111–129.
- Rodrigues T, Reker D, Schneider P, Schneider G. Counting on natural products for drug design. *Nat Chem*. 2016;8(6):531–541.
- Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. *Drug Discov Today Technol*. 2004;1(4):337–341.
- Wolfender JL, Nuzillard JM, van der Hooft JJJ, Renault JH, Bertrand S. Accelerating metabolite identification in natural product research. *Anal Chem*. 2019;91(1):704–742.
- Timmers M, Vekemans K, Vermijlen G, *et al*. Impact of computational chemistry and artificial intelligence on drug design. *J Comput Chem*. 2021;42(21):1612–1629.
- Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. *Chin J Nat Med*. 2013;11(2):110–120.
- Aniszewski T. Alkaloids: Chemistry, Biology, Ecology, and Applications. 2nd ed. Amsterdam: Elsevier; 2015.
- Moudi M, Go R, Yien CYS, Nazre M. Vinca alkaloids. *Int J Prev Med*. 2013;4(11):1231–1235.
- Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. *Metabolism*. 2008;57(5):712–717.
- Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. *J Nutr Sci*. 2016;5:e47.
- Tungmunnithum D, Thongboonyou A, Pholboon A, Yangsabai A. Flavonoids and other phenolic compounds from medicinal plants. *Medicines (Basel)*. 2018;5(3):93.
- Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy. *Biochem Pharmacol*. 2012;83(1):6–15.
- Khan N, Mukhtar H. Tea polyphenols in promotion of human health. *Nutrients*. 2019;11(1):39.
- Tholl D. Biosynthesis and biological functions of terpenoids in plants. *Adv Biochem Eng Biotechnol*. 2015;148:63–106.
- Tu Y. Artemisinin—a gift from traditional Chinese medicine to the world (Nobel Lecture). *Angew Chem Int Ed Engl*. 2016;55(35):10210–10226.
- Weaver BA. How Taxol/paclitaxel kills cancer cells. *Mol Biol Cell*. 2014;25(18):2677–2681.
- Liu Q. Triptolide and its expanding multiple pharmacological functions. *Int Immunopharmacol*. 2011;11(3):377–383.
- Vincken JP, Heng L, de Groot A, Gruppen H. Saponins, classification and occurrence in the plant kingdom. *Phytochemistry*. 2007;68(3):275–297.

23. Lee SM, Bae BS, Park HW, *et al.* Characterization of Korean Red Ginseng. *J Ginseng Res.* 2015;39(4):384–391.
24. Radad K, Moldzio R, Rausch WD. Ginsenosides and their CNS targets. *CNS Neurosci Ther.* 2011;17(6):761–768.
25. Fiore C, Eisenhut M, Krausse R, *et al.* Antiviral effects of *Glycyrrhiza* species. *Phytother Res.* 2008;22(2):141–148.
26. Sova M, Saso L. Hydroxycinnamic acids: natural sources and biological activities. *Nutrients.* 2020;12(8):2190.
27. Ma Q. Role of Nrf2 in oxidative stress and toxicity. *Annu Rev Pharmacol Toxicol.* 2013;53:401–426.
28. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin. *AAPS J.* 2013;15(1):195–218.
29. Prassas I, Diamandis EP. Novel therapeutic applications of cardiac glycosides. *Nat Rev Drug Discov.* 2008;7(11):926–935.
30. Menger L, Vacchelli E, Adjemian S, *et al.* Cardiac glycosides induce immunogenic cell death. *Sci Transl Med.* 2012;4(143):143ra99.
31. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer. *Free Radic Biol Med.* 2010;49(11):1603–1616.
32. Baird L, Yamamoto M. Regulation of the KEAP1–NRF2 pathway. *Mol Cell Biol.* 2020;40(13):e00099-20.
33. Hybertson BM, Gao B, Bose SK, McCord JM. Oxidative stress and Nrf2 activation. *Mol Aspects Med.* 2011;32(4–6):234–246.
34. Liu T, Zhang L, Joo D, Sun SC. NF- κ B signaling in inflammation. *Signal Transduct Target Ther.* 2017;2:17023.
35. Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids. *J Pharmacol Sci.* 2004;96(3):229–245.
36. Bode AM, Dong Z. The functional contrariety of JNK. *Mol Carcinog.* 2007;46(8):591–598.
37. Jung HA, Min BS, Yokozawa T, *et al.* Anti-Alzheimer activities of *Coptidis Rhizoma* alkaloids. *Biol Pharm Bull.* 2009;32(8):1433–1438.
38. Proença C, Freitas M, Ribeiro D, *et al.* α -Glucosidase inhibition by flavonoids. *J Enzyme Inhib Med Chem.* 2017;32(1):1216–1228.
39. Navarro-Perán E, Cabezas-Herrera J, García-Cánovas F, *et al.* Antifolate activity of tea catechins. *Cancer Res.* 2005;65(6):2059–2064.
40. Messina M. Soy and health update. *Nutrients.* 2016;8(12):754.
41. Pertwee RG. CB1 and CB2 receptor pharmacology of plant cannabinoids. *Br J Pharmacol.* 2008;153(2):199–215.
42. Lee YY, Park JS, Lee EJ, *et al.* Anti-inflammatory mechanism of ginseng saponin Rh3. *J Agric Food Chem.* 2015;63(13):3472–3480.
43. Procházková D, Boušová I, Wilhelmová N. Antioxidant and prooxidant properties of flavonoids. *Fitoterapia.* 2011;82(4):513–523.
44. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases. *Phytother Res.* 2010;24(10):1423–1432.
45. Tanaka T, de Azevedo PS, Durán N, *et al.* Colorectal carcinogenesis models. *J Oncol.* 2012;2012:342618.
46. Zhang Y, Talalay P, Cho CG, Posner GH. Anticarcinogenic enzymes from broccoli. *Proc Natl Acad Sci U S A.* 1992;89(6):2399–2403.
47. Rathore K, Choudhary S, Wang HC. Green tea catechins and ERK pathway activation. *Carcinogenesis.* 2012;33(1):174–183.
48. Fulda S. Resveratrol and derivatives in cancer prevention. *Drug Discov Today.* 2010;15(17–18):757–765.
49. Cragg GM, Kingston DGI, Newman DJ. Anticancer Agents from Natural Products. 2nd ed. Boca Raton (FL): CRC Press; 2011.
50. Pommier Y. Topoisomerase I inhibitors. *Nat Rev Cancer.* 2006;6(10):789–802.
51. Gordaliza M, García PA, del Corral JM, Castro MA, Gómez-Zurita MA. Podophyllotoxin and derivatives. *Toxicon.* 2004;44(4):441–459.
52. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. *Nat Rev Cancer.* 2005;5(6):423–435.